This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Carcinoma, Transitional Cell
Information about Carcinoma, Transitional Cell: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Carcinoma, Transitional Cell
Most recent studies have shown that Carcinoma, Transitional Cell shares some biological mechanisms with adenocarcinoma, bladder-neoplasm, carcinoma, carcinoma-in-situ, cell-invasion, kidney-neoplasm, malignant-neoplasm-of-urinary-bladder, malignant-neoplasms, malignant-paraganglionic-neoplasm, malignant-squamous-cell-neoplasm, neoplasm-invasiveness, neoplasm-metastasis, neoplasm-recurrence-local, neoplasms, neoplasms-multiple-primary, prostatic-neoplasms, superficial-bladder-cancer, transitional-cell-carcinoma-of-bladder, ureteral-neoplasms, urologic-neoplasms.
Among the many pathways, these few ones have gauged particular interests from scientists studying Carcinoma, Transitional Cell, and have been seen in publications frequently: Angiogenesis, Cell Adhesion, Cell Cycle, Cell Death, Cell Differentiation, Cell Growth, Cell Proliferation, Coagulation, Dna Repair, Drug Resistance, Excretion, Hypersensitivity, Immune Response, Interphase, Localization, Methylation, Mismatch Repair, Pathogenesis, S Phase, Secretion
Quite a number of genes have been found to play important roles in Carcinoma, Transitional Cell, such as ACAT1, BAG6, CDKN1A, CDKN2A, EGFR, ERBB2, IL2, KLK3, KRT20, KRT7, PCNA, SFXN1, SLC25A5, TNF, TP53, VEGFA. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.